Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 15, 2013, Pages 6115-6120

  Pollinger, Klaus ^a   Hennig, Robert ^a   Ohlmann, Andreas ^a   Fuchshofer, Rudolf ^a   Wenzel, Rebecca ^a   Breunig, Miriam ^a   Tessmar, Joerg ^a   Tamm, Ernst R ^a   Goepferich, Achim ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Age related macular degeneration; Choroid; Diabetic retinopathy; Ligand receptor interaction; Neovascularization

Indexed keywords

NANOPARTICLE; QUANTUM DOT; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CAPILLARY ENDOTHELIUM; CELL INTERACTION; CHOROID CAPILLARY LAYER; CIRCULATION TIME; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGAND BINDING; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RETINA CAPILLARY; TARGET CELL;

ANIMALS; ASTROCYTES; CAPILLARIES; CELLS, CULTURED; CHOROID; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN ALPHAVBETA3; LIGANDS; MACULAR DEGENERATION; MALE; MICE; MICROCIRCULATION; NANOPARTICLES; NANOTECHNOLOGY; PROTEIN BINDING; QUANTUM DOTS; RATS; RATS, WISTAR; RETINA; RETINAL VESSELS; TIME FACTORS;

MUS MUSCULUS;

EID: 84876067525     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220281110     Document Type: Article

References (39)

1. Coorey NJ, Shen W, Chung SH, Zhu L, Gillies MC (2012) The role of glia in retinal vascular disease. Clin Exp Optom 95(3):266-281.
2. Lee J-H, Pidaparti RM, Atkinson GM, Moorthy RS (2012) Design of an implantable device for ocular drug delivery. J Drug Deliv 2012:527516.
3. Chopdar A, Chakravarthy U, Verma D (2003) Age related macular degeneration. BMJ 326(7387):485-488.
4. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group (2004) The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27(7):1647-1653.
5. Meleth AD, et al. (2005) Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 46(11):4295-4301.
6. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047-1053.
7. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J (2012) Prevalence of diabetic retinopathy in various ethnic groups: A worldwide perspective. Surv Ophthalmol 57(4):347-370.
8. Giuliari GP (2012) Diabetic retinopathy: Current and new treatment options. Curr Diabetes Rev 8(1):32-41.
9. Kumar B, Gupta SK, Saxena R, Srivastava S (2012) Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med 58(2):132-139.
10. Avery RL, et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3):363-372, e5.
11. Maeshima K, Utsugi-Sutoh N, Otani T, Kishi S (2004) Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy. Retina 24(4):507-511.
12. Martidis A, et al. (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109(5):920-927.
13. Moshfeghi DM, et al. (2003) Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 136(5):791-796.
14. Singh SR, et al. (2009) Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 16(5):645-659.
15. Salehi-Had H, et al. (2011) Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization. PLoS ONE 6(4):e18864.
16. Krzystolik MG, et al. (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120(3):338-346.
17. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE (2000) Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 157(1):135-144.
18. Yoshida T, Gong J, Xu Z, Wei Y, Duh EJ (2012) Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). Exp Eye Res 94(1):41-48.
19. Vincent JA, Mohr S (2007) Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56(1):224-230.
20. Gomes Bittencourt M, et al. (2012) New treatment options for noninfectious uveitis. Dev Ophthalmol 51:134-161.
21. Hodivala-Dilke K (2008) alphavbeta3 integrin and angiogenesis: A moody integrin in a changing environment. Curr Opin Cell Biol 20(5):514-519.
22. Eliceiri BP, Cheresh DA (1999) The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest 103(9):1227-1230.
23. Hild WA, Breunig M, Goepferich A (2008) Quantum dots: Nano-sized probes for the exploration of cellular and intracellular targeting. Eur J Pharm Biopharm 68(2):153-168.
24. Walling MA, Novak JA, Shepard J R E (2009) Quantum dots for live cell and in vivo imaging. Int J Mol Sci 10(2):441-491.
25. Aumailley M, et al. (1991) Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 291(1):50-54.
26. Franze K, et al. (2007) Muller cells are living optical fibers in the vertebrate retina. Proc Natl Acad Sci USA 104(20):8287-8292.
27. Newman EA (2003) New roles for astrocytes: Regulation of synaptic transmission. Trends Neurosci 26(10):536-542.
28. Zhang LW, Monteiro-Riviere NA (2009) Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol Sci 110(1):138-155.
29. Tekle C, Deurs Bv, Sandvig K, Iversen T-G (2008) Cellular trafficking of quantum dotligand bioconjugates and their induction of changes in normal routing of unconjugated ligands. Nano Lett 8(7):1858-1865.
30. Ferreira L, et al. (2008) Human embryoid bodies containing nano-and microparticulate delivery vehicles. Adv Mater (Deerfield Beach Fla) 20:2285-2291.
31. Ivaska J, Heino J (2011) Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annu Rev Cell Dev Biol 27:291-320.
32. Schipper ML, et al. (2007) microPET-based biodistribution of quantum dots in living mice. J Nucl Med 48(9):1511-1518.
33. Praetner M, et al. (2010) The contribution of the capillary endothelium to blood clearance and tissue deposition of anionic quantum dots in vivo. Biomaterials 31(26):6692-6700.
34. Cai W, et al. (2006) Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 6(4):669-676.
35. Haubner R, et al. (2005) Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2(3):e70.
36. Shi W, Bartlett JS (2003) RGD inclusion in VP3 provides adeno-associated virus type 2(AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 7 (4):515-525.
37. Cai W, Chen X (2008) Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc 3(1):89-96.
38. Seitz R, Hackl S, Seibuchner T, Tamm ER, Ohlmann A (2010) Norrin mediates neuroprotective effects on retinal ganglion cells via activation of the Wnt/beta-catenin signaling pathway and the induction of neuroprotective growth factors in Muller cells. J Neurosci 30(17):5998-6010.
39. Fuchshofer R, Birke M, Welge-Lussen U, Kook D, Lütjen-Drecoll E (2005) Transforming growth factor-beta 2 modulated extracellular matrix component expression in cultured human optic nerve head astrocytes. Invest Ophthalmol Vis Sci 46(2):568-578.